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ABSTRACT
Increasingevidencesuggeststhatthecytokinetrans-
forming growth factor-b (TGF-b) inhibits the devel-
opment of atherosclerosis. The lipoprotein lipase
(LPL) enzyme expressed by macrophages has been
implicated in the pathogenesis of atherosclerosis by
stimulating the uptake of lipoprotein particles.
Unfortunately, the action of TGF-b on the expression
of LPL in macrophages remains largely unclear. We
show that TGF-b inhibits LPL gene expression at the
transcriptional level. Transient transfection assays
reveal that the  31/1187 sequence contains the min-
imal TGF-b-responsive elements. Electrophoretic
mobility shift assays show that Sp1 and Sp3 inter-
act with two regions in the  31/1187 sequence.
Mutations of these Sp1/Sp3 sites abolish the TGF-
b-mediated suppression whereas multimers of the
sequence impart the response to a heterologous pro-
moter. TGF-b has no effect on the binding or steady-
statepolypeptidelevelsofSp1andSp3.Theseresults,
therefore, suggest a novel mechanism for the TGF-b-
mediated repression of LPL gene transcription that
involves regulation of the action of Sp1 and Sp3.
INTRODUCTION
The enzyme lipoprotein lipase (LPL; EC 3.1.1.34) plays a key
role in the overall lipid metabolism and transport by catalysing
the hydrolysis of the triacylglycerol component of chylo-
microns and very low-density lipoproteins, thereby providing
non-esteriﬁed fatty acids and 2-monoacylglycerols for tissue
utilization (1). LPL issynthesized by several tissues/cell types,
with the enzyme expressed by the cells of the vascular wall,
particularly macrophages, implicated to play a key role in the
pathogenesis of atherosclerosis (1,2). For example, LPL is
expressed in the lesion where macrophage-derived foam
cells represent the predominant site for the synthesis of the
enzyme (3). In addition, inbred murine strains with elevated
levels of macrophage LPL show an increased susceptibility to
atherosclerosis (4). Furthermore, macrophage LPL expression
is increased in patients with diabetes and heterozygous famil-
ial hypercholesterolemia (5,6), and this may be responsible, at
least in part, for the high incidence of atherosclerosis in such
individuals. Moreover, a marked decrease in diet-induced
atherosclerosis has been seen in chimeric mice that are deﬁ-
cient for macrophage LPL expression (7–9) and, conversely,
macrophage-speciﬁc expression of human LPL accelerates
atherosclerosis in transgenic apolipoprotein E (apoE)-
deﬁcient mice (10). This pro-atherogenic action of LPL
involves both its catalytic function and non-catalytic ‘bridging
action’ that allows it to interact simultaneously with both
speciﬁc cell surface proteins/receptors and plasma lipopro-
teins, thereby increasing the uptake of the latter by macro-
phages and, thus, leads to foam cell formation (1,2).
The transformation of macrophages into foam cells is inhib-
ited by cytokines such as transforming growth factor-b
(TGF-b) by the regulation of key genes that are involved in
modulating cholesterol inﬂux and efﬂux (11–13). For exam-
ple, TGF-b has been shown to inhibit the expression of genes
encoding the scavenger receptors A and CD36 (12–14), which
are involved in cholesterol import, and stimulating the expres-
sion of a number of genes implicated in mediating cholesterol
efﬂux such as ATP-binding cassette transporter-A1 (ABCA1)
and -G1 (ABCG1) (11,12). The anti-atherogenic action of
TGF-b is not restricted to the control of macrophage foam
cell formation but also extends to other functions. For
example, the cytokine has anti-inﬂammatory properties, as
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TGF-b knockout mice (15). In addition, the cytokine induces
the expression of tissue inhibitors of metalloproteinases (16),
inhibits nitric oxide and superoxide production (17), and
increases the expression of IL-1 receptor antagonist (18). In
further support of an anti-atherogenic role of TGF-b, inhibi-
tion of its signalling by use of neutralizing antibodies has
been shown to accelerate the development of atherosclerotic
lesions in apoE-deﬁcient mice (19). It has also been suggested
that the protective effect of tamoxifen in the formation of lipid
lesions in apoE knockout mice is mediated through increased
production of TGF-b in the aorta (20). Additionally, in apoE-
deﬁcient mice treated with anti-CD40 antibody, increased
levels of TGF-b have been found to be associated with
lipid poor lesions (21). More recently, low TGF-b levels
have been identiﬁed as a risk factor for the high incidence
of atherosclerosis in patients with end-stage renal disease (22),
and the disruption of TGF-b signalling in T cells has been
shown to accelerate atherosclerosis in murine models of the
disease (23).
In the light of the TGF-b-regulated expression of several
key genes in macrophages that are involved in modulating
lipoprotein uptake and foam cell formation, it is essential
that a detailed understanding is obtained of the signalling
pathway(s) and the transcription factors that are required
for such responses. Such studies will not only better our under-
standing of the molecular basis of foam cell formation and
atherogenesis but, in the longer term, may also lead to the
identiﬁcation of potentially novel targets for therapeutic inter-
vention. TGF-b exerts its cellular actions by interacting with a
heteromeric complex of transmembrane serine/threonine
kinases, the type I and the type II receptors (24,25). In
relation with the intracellular signalling pathways, advances
have been made in the area of activation of gene transcription
bythe cytokine (24,25).Thus, on phosphorylation by activated
type I receptor, Smad2or Smad3 form complexes with Smad4.
The complex then translocates to the nucleus where it exerts
transcriptional activities either directly by interacting with
Smad-responsive elements in the regulatory regions of target
genes, or indirectly through association with other transcrip-
tion factors (24,25). Unfortunately, our current understanding
of the mechanisms by which TGF-b inhibits gene expression
remains enigmatic and this is mainly due to the limited
research that has been carried out in this area. We have, there-
fore, investigated this important aspect using LPL as a model
gene. We show here that TGF-b inhibits the expression of the
LPL gene in macrophages at the transcriptional level. In addi-
tion, we delineate the cis-acting regulatory sequences that are
involved in the response and demonstrate a critical role for the
Sp1-binding sites in the action of TGF-b. These studies, there-
fore, provide novel insights into the molecular mechanisms
that are required for the TGF-b-mediated inhibition of gene
transcription.
MATERIALS AND METHODS
Reagents
The human myeloid leukaemic U937, the mouse macrophage
J774.2 and the human hepatoma Hep3B cell lines were from
the European Collection of Animal Cell Cultures. All the cell
culture reagents were purchased from Autogen-Bioclear,
Sigma or Invitrogen. Antisera against Sp1 and Sp3 were
from Santa Cruz.
Cell culture
The cell lines were maintained in either DMEM (J744.2 and
Hep3B) or RPMI 1640 (U937), which was supplemented with
10% (v/v) heat-inactivated foetal calf serum (HI-FCS; 56 C,
45 min), 2 mM L-glutamine, 100 U/ml penicillin and 100 mg/
ml streptomycin (designated as complete medium). The cul-
tures were maintained at 37 C in a humidiﬁed atmosphere
containing 5% (v/v) CO2 in air. For human monocyte-
derived macrophages, blood was collected from healthy
volunteers into a syringe containing an equal volume of sterile
2% (w/v) dextran in 1· PBS containing 0.8% (w/v) tri-sodium
citrate, and was allowed to stand for 30 min to permit eryth-
rocyte sedimentation. The upper layer was collected, under-
layered with Lymphoprep
TM (Nycomed Pharmaceuticals)
[2:1 (v/v) supernatant/Lymphoprep
TM] and centrifuged at
800 g for 20 min. The resultant interface was collected and
washed 6–8 times with PBS-0.4% (w/v) tri-sodium citrate to
remove contaminating platelets. Monocytes were plated out in
75cm
2 ﬂasks in complete medium, as above except containing
5% (v/v) serum, and were allowed to adhere to the surface for
6hin a humid incubatorat 37 Ccontaining 5%(v/v)CO2.The
cells were then washed twice with PBS to remove any other
mononuclear cells, fresh medium was added and the differ-
entiation allowed to continue for 7 days. The homogeneity of
macrophages was veriﬁed by morphological analysis. Unless
otherwisestated,thecellswere preincubatedfor4hinmedium
containing reduced (0.5%) HI-FCS before stimulation with
TGF-b (26–28).
RT–PCR
Total cellular RNA was prepared using the RNeasy
TM total
RNA isolation kit (Qiagen) according to the manufacturer’s
instructions. Each isolated RNA sample (1 mg) was then sub-
jected to RT–PCR essentially as described before (29–31)
except that the annealing temperature and the total number
of cycles varied: 21 cycles and 60 C and 24 cycles and 55 C
for murine and human LPL, respectively, 9 cycles and 62 C
for 28S rRNA, 16 cycles at 60 C for glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) and 18 cycles at 58 C
for b-actin. These conditions were in the exponential phase of
ampliﬁcation and, therefore, provided a direct correlation
between the amount of products and the RNA template abund-
ance in the samples. The sequences of the primers were 50-
CATTTACCAGGGGGTCAC-30 and 50-AGGCAGAGCCC-
TTTCTCA-30 for mouse LPL; 50-GAGATTTCTCTGTAT-
GGCACC-30 and 50-CTGCAAATGAGACACTTTCTC-30 for
human LPL; 50-CCCTTCATTGACCTCAACTACATGG-30
and 50-AGTCTTCTGGGTGGCAGTGATGG-30 for GAPDH;
50-TGAACTATGCTTGGGCAGGG-30 and 50-AGCGCCAT-
CCATTTTCAGGG-30 for 28S rRNA; and 50-TGGAGAAGA-
GCTATGAGCTGCCTG-30 and 50-GTCCCACCAGACACC-
ACTGTGTTG-30 for b-actin. The PCR products were size-
fractionated on a 2% (w/v) agarose gel, photographed using a
Syngene gel documentation system (GRI) and quantiﬁed using
the Gene Tools computer package (Syngene).
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The method employed was a modiﬁcation of that used by
Hildebrandt and Neufer (32). The cells were harvested by
scraping them into the medium which was then removed
from the ﬂask and centrifuged at 1000 g for 5 min. The res-
ulting cell pellet was washed three times by resuspension in 1
ml of ice-cold PBS and microcentrifugation at 10000 g for 30
s. After the ﬁnal wash, the supernatant was discarded and 200
ml of ice-cold buffer A [10 mM HEPES, pH 7.9, 1.5 mM
MgCl2, 10 mM KCl, 0.5 mM DTT, 0.5 mM phenylmethyl-
sulfonyl ﬂuoride (PMSF), 1 mg/ml pepstatin A, 10 mg/ml
aprotinin, 10 mg/ml leupeptin and 10 mg/ml type I-S soybean
trypsin inhibitor] was added. The mixture was brieﬂy vortexed
and incubated on ice for 5 min. The cells were lysed by
pipetting up and down 10 times in a 100 ml Hamilton syringe
and centrifuged at 700 g for 10 min at 4 C. The resulting crude
nuclear pellet was gently suspended in 10 ml of ice-cold buffer
B [15 mM HEPES, pH 7.9, 60 mM KCl, 3 mg/ml BSA, 300
mM sucrose, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5
mM spermidine, 0.15 mM spermine, 0.5 mM PMSF, 2 mg/ml
leupeptin and 0.5% (v/v) Triton X-100] and was centrifuged at
700 g for 10 min at 4 C. Pelleted nuclei were resuspended in
10 ml of ice-cold buffer C (15 mM HEPES, pH 7.9, 60 mM
KCl, 3 mg/ml BSA, 300 mM sucrose, 0.1 mM EDTA, 0.1 mM
EGTA, 1 mM DTT, 0.5 mM spermidine, 0.15 mM spermine,
0.5 mM PMSF, 2 mg/ml leupeptin and 5 mM magnesium
acetate) and centrifuged as above. Final nuclei pellets were
resuspended in 230 ml storage buffer [40% (v/v) glycerol, 75
mM HEPES, pH 7.9, 60 mM KCl, 15 mM NaCl, 5 mM
magnesium acetate, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM
DTT, 0.5 mM spermidine, 0.15 mM spermine, 2 mg/ml apro-
tinin and 2 mg/ml leupeptin], quick frozen in liquid nitrogen
and stored at  70 C. Nuclear ‘run-on’ reactions were carried
out by incubation of nuclei (160 ml), previously thawed on ice,
with 2· reaction buffer [20% (v/v) glycerol, 100 mM KCl, 10
mM MgCl2,4.5 mM DTT, 1.2 mM ATP, 0.6 mM each of CTP,
GTPandUTP,80U/mlRNasinribonucleaseinhibitor,0.5mM
spermidine, and 0.15 mM spermine] for 15 min at 22 C. Nuc-
lei were then subjected to DNaseI treatment (20 U) in the
presence of 1 mM CaCl2 for 15 min at 37 C. This was fol-
lowed by digestion of nuclear proteins by the addition of 10·
digestion buffer [100 mM Tris–HCl, pH 8.0, 10 mM EDTA,
5% (w/v) SDS and 100 mg/ml proteinase K] and incubation
for 30 min at 37 C. Nuclear RNA was extracted in a ﬁnal
volume of 30 ml using the RNeasy total RNA isolation kit
(Qiagen). Subsequent RT–PCRs were carried out as des-
cribed above.
LPL activity assay
Samples for the determination of the heparin-releasable LPL
activity were prepared as described previously (27,28). The
activity was then determined using ConﬂuolipTM Continuous
Fluorometric Lipase kit (Progen) (33).
Preparation of manipulated LPL promoter–reporter
DNA constructs
A series of DNA constructs, containing 50 truncations of the
LPL promoter in the p19Luc vector, were a gift from
Dr J. M. Gimble (34). The LPL sequences in these constructs
were cloned in front of the luciferase reporter gene in the
pGL2-Basic vector (Promega). The preparation of DNA
constructs containing mutations of the Sp1 sites (Sp1M44,
Sp1M62/65 and Sp1M44/62/65) and those with four copies
of the Sp1 sites at position +44, +62 and +65, or the +38 to the
+75 region, that are all linked to a heterologous minimal SV40
promoter in the pGL2-promoter vector has been described
previously (26). For the preparation of a DNA construct con-
taining the  31 to +9 region linked to a minimal SV40
promoter, the following oligonucleotides were synthesized:
50-CCGGGTCACTTAAACAGCTGTGCAGTGGAAACAG-
TGTCAGACTC-30 and 50-TCGAGAGTCTGACACTGTTT-
CCACTGCACAGCTGTTTAAGTGAC-30. These were desi-
gned in such a manner that, following annealing, they had
overhangs that allowed their direct cloning into the XmaI
and XhoI sites of the pGL2-promoter vector (26,35). The
sequences of all the DNA constructs used were veriﬁed by
DNA sequencing.
Transient transfection assays
U937 or Hep3B cells were transfected using Superfect
TM
(Qiagen) (26). The cells were harvested by centrifugation
(1000 g for 5 min), resuspended in appropriate medium con-
taining 3% (v/v) HI-FCS for U937 (26) and 10% (v/v) HI-FCS
for Hep3B (30), subcultured into 6-well plates at a density of
1.5 · 10
6 cells/well, and incubated for 4 h. The DNA/Super-
fect
TM complex was then prepared by diluting the DNA to
50 ml/mg DNA with appropriate medium. Superfect
TM (1.5–
4 ml/mg DNA) was added and the mixture was vortexed and
incubated at room temperature for 10 min. The complex was
then diluted with the appropriate medium (600 ml/mgo fD N A )
and added to the cells. For Hep3B, the cells were returned to
the incubator for 6 h. The medium was then changed and
the cells incubated for 24 h in the absence or the presence
of 30 ng/ml TGF-b. For U937, the cells were returned to the
incubator for a further 3 h before being centrifuged as above
and washed with 10 ml of RPMI 1640. The cells were resus-
pended at a density of 1.5 · 10
6 cells/ml in RPMI 1640 sup-
plemented with 3% (v/v) FCS and plated out at 2 ml/well in 6-
well plates. The cells were then either incubated with phorbol
12-myristate 13-acetate (PMA) (1 mM) in the absence or the
presence of TGF-b1 (30 ng/ml) for 12 h (26) or ﬁrst differ-
entiated with PMA for 12 h and then treated with the
cytokine for a further 12 h (cells stimulated for 24 h with
PMA were used for comparison in this case). Similar results
were obtained with both experimental approaches. The luci-
ferase and the b-galactosidase activities in the cell extracts
were then determined using commercially available kits
(Promega). The luciferase activity was normalized to the
b-galactosidase values or, in some cases the total protein
levels, with each transfection being carried out in triplicate
and repeated at least three times.
Preparation of whole cell extracts
Whole cell extracts were prepared essentially as described
previously (26,29,30,35). Protease inhibitors (0.5 mM PMSF,
2 mM benzamidine, 1 mg/ml pepstatin A, 10 mg/ml aprotinin
and 2.5 mg/ml leupeptin) and DTT (0.5 mM) were added to all
buffers before use. The concentration of proteins in extracts
was determined using the microBCA protein assay kit accord-
ing to the manufacturer’s instructions (Pierce).
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EMSA was carried out essentially as reported previously
(26,29,30,35). The sequences of the oligonucleotides used
for EMSA were as follows:  31/+8, 50-GTCACTTAAACAG-
CTGTGCAGTGGAAACAGTGTCAG-30 and 50-AGTCTG-
ACACTGTTTCCACTGCACAGCTGTTTAAGT-30; +9/+49,
50-CTCGATTTCTCCTCCTACTCCTCCTCCGAGGAATT-
CT-30 and 50-GGGCAGAATTCCTCGGAGGAGGAGTAG-
GAGGAGAAAT-30; +46/+90, 50-GCCCCCTGTAACTGTT-
CTGCCCTCCCCTTTAAAGGTTGACTT-30 and 50-GGCA-
AGTCAACCTTTAAAGGGGAGGGCAGAACAGTTACA-
GGG-30; +90/+118, 50-GCCCTACGGCGCTCCACCGCGC-
TCCAGT-30 and 50-AGGACTGGAGCGCGGTGGAGCGC-
CGTAG-30; +119/+160, 50-CTTGCGCCTCCTGCTCAAC-
CCGCTCCTGACTGCCCACGC-30 and 50-GCGGCGTGG-
GCAGTCAGGAGCGGGTTGAGCAGGAGGCG-30;a n d
+159/+195, 50-CGCGTAGTTCCAGCAGCAAAGCAGAA-
GGGTGCA-30 and 50-CCGGTGCACCCTTCTGCTTTGCT-
GCTGGAACTA-30.
SDS–PAGE and western-blot analysis
Samples (10 mg whole cell extracts) were size-fractionated
under reducing conditions using 7.5–15% (w/v) polyacrylam-
ide gels containing SDS (26–30). For western-blot analysis,
the proteins on the gel were transferred onto Immobilon-P
PVDFmembranes(Millipore)byblotting(26–30).Theblotted
membranes were incubated ﬁrst for 1 h at room temperature in
blocking solution [1· Tris-buffered saline (TBS) containing
5% (w/v) non-fat milk powder and 0.05% (w/v) Tween-20] in
order to reduce any non-speciﬁc interaction of the antiserum
with the membrane. Following three washes of 5 min each
with 1· TBS containing 0.05% (v/v) Tween-20, the membrane
was incubated with the primary antibody for 1 h in 1· TBS
containing 5% (w/v) non-fat milk powder and 0.1% (v/v)
Tween-20. After washes as above, the membrane was incub-
ated with secondary horseradish peroxidase (HRP)-conjugated
antibodies (goat anti-rabbit IgG or mouse anti-goat IgG) for
30 min at room temperature in 1· TBS containing 5% (w/v)
non-fat milk powder and 0.05% (v/v) Tween-20. After wash-
ing once again as above, the membranes were developed using
an enhanced chemiluminescence detection kit (Amersham)
and XAR sensitive ﬁlm (Kodak). The sizes of the proteins
were determined by comparison with Rainbow molecular
weight markers (Amersham) that had been subjected to elec-
trophoresis and blotting on the same gel as the test samples.
RESULTS
TGF-b inhibits LPL gene expression in macrophages
at the transcriptional level
We have previously employed the murine J774.2 cell line to
investigate the regulation of LPL gene expression in macro-
phages by cytokines (26–28). The work, both in our laboratory
and others have shownthatthe regulationofLPLandanumber
of other genes in this cell line correlates with what is seen in
primarymacrophagecultures[(26–28)andreferencestherein].
For the initial experiments, the cells were incubated with
10 ng/ml of TGF-b for 20 h, a period when maximal changes
to a range of factors in LPL expression are seen (26–28), and
RNA was used for RT–PCR with primers against LPL and the
control b-actin. A similar experiment using PDGF, which has
been shown previously to induce LPL mRNA expression in
macrophages (36), was included for comparative purposes. As
expected, PDGF increased LPL mRNA expression
(Figure1A). On the other hand, incubation of the cells with
TGF-b led to a marked decrease in LPL mRNA expression
(Figure 1A). Further experiments showed that TGF-b
decreased LPL mRNA expression in a time-dependent man-
ner, with a maximal reduction of  60% produced at 20 h (data
not shown). The proﬁle was similar to that seen previously for
LPL in response to a number of other factors (27). In order to
investigate the dose–response of TGF-b action, the cells were
treated for 20 h with different concentrations of cytokine. The
range of concentrations used was based on an extensive survey
of TGF-b-mediated regulation of gene expression. As shown
in Figure 1B, a concentration-dependent reduction of LPL
mRNA expression was observed with maximal decrease of
 70% seen with 30 ng/ml of the cytokine. Finally, in order to
rule out the possibility that the TGF-b-mediated decrease
in LPL mRNA expression was a peculiar property of the
C PDGF C TGF-β β
LPL
β-actin
M   0    1 2 5 10 20 30 (TGF-β, ng/ml)
LPL
GAPDH
M   0    1 2 5 10 20 30 (TGF-β, ng/ml)
GAPDH
  0h  1h  3h   12h   24h 
LPL 
GAPDH
(A) 
(B) 
(C) 
Figure1.TGF-bdecreasesLPLmRNAexpressioninmacrophages.(A)J774.2
macrophages were either left untreated (C) or stimulated for 20 h with PDGF-
BB (PDGF; 10 ng/ml) or 10 ng/ml TGF-b1 (TGF-b); (B) J774.2 macrophages
were exposed to the indicated concentration of the cytokine for 20 h; and (C)
primary cultures of human monocyte-derived macrophages were incubated for
the indicated period of time with 30 ng/ml of TGF-b1. Total RNA was isolated
andsubjectedtoRT–PCRusingprimersforLPL,b-actinorGAPDHasshown.
The amplification products were size-fractionated by agarose gel electrophor-
esis.Thedatashownarerepresentativeofatleasttwoindependentexperiments.
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ary cultures of human monocyte-derived macrophages. As
expected, TGF-b decreased LPL mRNA expression with max-
imal reduction of  70% seen at 12 h (Figure 1C).
We next investigated whether the TGF-b-mediated reduc-
tion of LPL mRNA expression in J774.2 macrophages was
accompanied by a corresponding decrease in the level of pro-
tein and enzymatic activity. As shown in Figure 2A, western-
blot analysis showed that the cytokine produced a dramatic
decrease in LPL protein levels. Similarly a decrease in the
functional, heparin-releasable LPL enzymatic activity was
seen (Figure 2B). The LPL activity assay was extended to
primary cultures of human monocyte-derived macrophages.
As shown in Figure 2C, TGF-b also decreased LPL activity in
these cells.
The TGF-b-mediated decrease in LPL mRNA expression
could be due to changes in either gene transcription or mRNA
stability. RT–PCR-based nuclear ‘run-on’ transcription assays
showed that the action of TGF-b on LPL mRNA expression
was mediated at the level of gene transcription (Figure 2D).
This conclusion was supported further by a similar proﬁle of
decay of LPL mRNA in the absence or the presence of TGF-b
following inhibition of gene transcription using actinomycin D
(data not shown). We next determined the regulatory
sequences and the transcription factors that are required for
the response.
Identification of the minimal regulatory region in the
LPL promoter that is required for the TGF-b-mediated
inhibition of LPL gene transcription
We have previously delineated the regulatory sequences that
are required for the inhibition of LPL gene transcription by
interferon g (IFN-g) via transient transfection of a range of 50
LPL promoter deletion constructs into the human U937 myel-
oid leukaemic cell line (26). Transfection of macrophages is
relatively difﬁcult and U937 cells, which have been employed
widely to delineate the sequence elements that are involved in
the regulation of macrophage gene transcription, yielded the
highest transfection efﬁciency from a range of monocyte/mac-
rophage cell lines examined (J774.2 macrophages could not be
transfected efﬁciently) [(26) and references therein]. Thus,
U937 monocytes were transfected with the LPL promoter–
luciferase DNA constructs, and luciferase activity in cell
extracts from differentiated macrophages, in the absence or
the presence of TGF-b, was then determined and normalized
to that of the b-galactosidase control. A schematic representa-
tion of the LPL promoter–luciferase DNA constructs used
along with binding sites for some key transcription factors
(1,2) are shown in Figure 3A. When the cells were transfected
using a DNA construct containing the largest LPL promoter
fragment ( 1824/+187),  50% reduction in the relative luci-
ferase activity was obtained (Figure 3B). Such a reduction was
comparable with that seen at the level of LPL mRNA expres-
sion, protein level and enzymatic activity (Figures 1 and 2).
A similar reduction in the relative luciferase activity of
 50% was seen with all the LPL promoter deletion constructs
(Figure 3B). This suggests that the  31 to +187 LPL promoter
region contains the minimal TGF-b responsive elements
(TGF-bREs) and was, therefore, investigated in detail. How-
ever, instead of mapping further the precise sequences that are
involved in the TGF-b response by analysing the effect of ﬁner
deletions or speciﬁc mutations in the  31/+187 region, we
decided to ﬁrst investigate the interaction of proteins with this
promoterregion using EMSA.Further studies couldthen focus
on those regions that interact with DNA-binding proteins.
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Figure 2. TheactionofTGF-bonLPLgeneexpressionismediatedatthelevel
of gene transcription. (A) Western-blot analysis was carried out using whole
cell extracts from J774.2 macrophages that were either left untreated (C) or
exposed to TGF-b1 (TGF-b; 30 ng/ml) for 20 h, and probed with antiserum
againstLPL.(BandC)J774.2cells(B)orprimaryculturesofhumanmonocyte-
derived macrophages (C) were either left untreated (Control) or stimulated for
20hwithTGF-b1(30ng/ml)asindicated.Theheparin-releasableLPLactivity
was then determined as described under Materials and Methods. The LPL
activity from cytokine-stimulated cells is represented as a percentage of the
activity of untreated control cells (assigned as 100%). Asterisks show signifi-
cantreductioncomparedtountreatedcells(**,P<0.005,*P<0.05).(D)J774.2
macrophageswereeitherleftuntreated(C)orstimulatedwithTGF-b1(TGF-b)
for 24 h. Following nuclear ‘run-on’ transcription assay, nuclear RNA was
extracted and subjected to RT–PCR using primers against LPL or GAPDH.
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and transfection assays
EMSA was carried out using the six double-stranded oligo-
nucleotides that spanned the  31/+187 region ( 31/+8, +9/
+49, +46/+90, +90/+118, +119/+160 and +159/+195) and
extracts from J774.2 macrophages that were either left
untreated or stimulated with TGF-b. Using the +90/+118,
+119/+160 and +159/+195 oligonucleotides, no speciﬁc
DNA–protein complexes could be detected even after long
autoradiographic exposures (Figure 4A). In contrast, speciﬁc
DNA–protein complexes were seen with the other three oli-
gonucleotides, thereby implicating the corresponding
sequences in the TGF-b response (Figure 4A). When the inter-
action of DNA-binding proteins to these three sites with
extracts from untreated and TGF-b-stimulated cells was
examined, an increase in binding to the  31/+8 region was
observed (Figure 4A). In contrast, no reproducible changes in
the binding of the proteins to the +9/+49 and +46/+90 region
could be seen in independent experiments (Figure 4A).
The +9/+90 region contains three recognition sequences for
the transcription factors Sp1 and Sp3 [a single site at position
+44 to +51 (antisense strand) and a dual site at position +62 to
+67 (antisense strand) and +65 to +71 (sense strand)] that are
highly conserved among the mouse, rat and the human gene
(Figure 4C). We have previously shown that these sites are
required for the IFN-g-mediated reduction of LPL gene trans-
cription(26).WenextevaluatedtheactivityofDNAconstructs
containing either a fragment with all these three Sp1/Sp3 sites
(+38/+75) or the  31/+9 region, to which a marginal increase
in binding was seen when extracts from TGF-b-treated cells
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ous, minimal SV40 promoter linked to a luciferase reporter
gene. The reporter gene activity from the  31/+9 region in
untreated macrophages was only marginal compared with that
produced by the +38/+75 region, thereby demonstrating the
major contribution by the Sp1/Sp3 sites to the constitutive
transcription of the LPL gene (Figure 4B). More importantly,
a marked, and statistically signiﬁcant, TGF-b-mediated reduc-
tion in reporter gene activity was seen with the +38/+75
sequence but not with the  31/+9 region (Figure 4B). Our
further studies, therefore, focused on these Sp1 and Sp3 sites
in the +38/+75 region.
As part of our previous studies on the regulation of LPL
gene transcription by IFN-g, we have conﬁrmed by using
competition EMSA and antibody supershift assay that Sp1
and Sp3 in extracts from untreated macrophages interact spe-
ciﬁcally with these three recognition sequences in the +9/+90
region (26). However, in contrast to the action of TGF-b
(Figure 4A), exposure of macrophages to IFN-g leads to a
dramatic decrease in the binding of factors to these sites
(26). In the light of this major difference, we decided to con-
ﬁrm that Sp1 and Sp3 also bound to the sites when extracts
from TGF-b-stimulated cells were used. For this, antibody
supershift assays were carried out using extracts from macro-
phages that had been treated with TGF-b for 24 h and antisera
against Sp1 and Sp3. As shown in Figure 4D, an inhibition of
speciﬁc DNA–protein complexes and the appearance of
slower migrating antibody–DNA–protein supershift complex
was seen when antisera against Sp1 and Sp3, but not the non-
immune serum, was included, thereby conﬁrming the interac-
tion of these two factors.
The Sp1/Sp3 sites are crucial for the TGF-b response
In order to evaluate the role of the identiﬁed Sp1/Sp3 recog-
nition sequences in the TGF-b response, the effect of muta-
tions of the single site at position +44, dual site at position
+62/+65 and all three sites in the  31/+187 context was
investigated by transfection assays. As expected, the relative
luciferase activity, normalized for the b-galactosidase internal
control, from the wild-type  31/+187 region was reduced by
 60% when the cells were treated with TGF-b (Figure 5A).
Mutations of the Sp1 sites have a marked effect on the pro-
moter activity of untreated cells (Figure 5A), thereby indic-
ating that the Sp1 sites are also necessary for constitutive
transcription. It is interesting to note that while the activity
of the DNA construct with mutations of the sites at position
+62 and +65 is only marginally more than that of the pro-
moterless pGL2-Basic vector, the activityofthe construct with
mutations of all three sites (positions +44, +62 and +65) was
substantially greater (Figure 5A). Although the exact reason
for this remains to be determined, it is likely that this may be
due to some form of interaction between the different Sp1/Sp3
sites. More importantly, however, the TGF-b response was
abolished with mutations of the dual site at positions +62
and +65 or mutations of all three sites (Figure 5A). In contrast,
a statistically signiﬁcant TGF-b response was seen with muta-
tion of the site at position +44 although the reduction was less
extensive compared to that seen with the  31/+187 region that
contains all three Sp1/Sp3 sites (Figure 5A). The TGF-b
response with the construct containing the mutation at position
+44 was most probably due to the presence of intact Sp1/Sp3
sites at positions +62 and +65. Overall, therefore, these results
suggest that the Sp1/Sp3 sites are required for the TGF-b-
mediated decrease in LPL promoter activity with the
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than that from the site at position +44.
In order to investigate the role of the Sp1 sites further, the
ability of multimers of the sites to confer the TGF-b response
to a heterologous promoter was investigated. For this, we used
DNA constructs containing four copies of the Sp1/Sp3 site at
position +44 or the dual site at positions +62 and +65 that are
linked to the minimal SV40 promoter in the pGL2-promoter
vector along with that containing the +38/+75 region (i.e. all
three Sp1/Sp3 sites). These constructs were transfected into
U937 cells and the relative luciferase activity was determined
in macrophages that were either left untreated or exposed to
TGF-b. As shown in Figure 5B, a TGF-b-mediated reduction
in reporter gene activity was obtained with all the LPL regu-
latory sequences used. Thus, the Sp1/Sp3 sites at positions +44
and +62/+65 are able to confer the TGF-b response to a het-
erologous promoter.
In order to rule out the possibility that the TGF-b-mediated
repression through the Sp1/Sp3 recognition sequences was a
peculiar property of macrophages, representative experiments
were repeated in the human hepatoma Hep3B cell line. A
TGF-b-inducible plasmid 3T3-Lux (37) was also included
for comparative purposes. Similar to U937 cells, a TGF-b-
mediated reduction of reporter gene activity was seen with
DNA constructs containing the +38/+75 region of the
LPL gene (all three Sp1/Sp3 sites) or four copies of the
dual site at position +62/+65, that are linked to the minimal
SV40 promoter (Figure 5C). In contrast, and as expected,
TGF-b induced the activity of the 3T3-Lux plasmid
(Figure 5C).
The action of TGF-b on LPL expression is independent
of any change in the steady-state levels of Sp1 and Sp3
EMSA showed that TGF-b had little effect on the binding of
Sp1 and Sp3 to regulatory sequences in the LPL gene (Figure
4A). This suggested that the cytokine probably had no effect
on the steady-state levels of Sp1 and Sp3 polypeptides. To
conﬁrm this assumption, J774.2 macrophages were treated
with TGF-b for 0, 6, 12, 18 and 24 h. Samples of proteins
from these time points were subjected to western-blot analysis
using antisera against Sp1 and Sp3. The Sp1 antiserum detec-
ted two closely migrating proteins with a molecular mass of
 112 kDa (Figure 6). It is likely that one of these represents a
post-translational variant of the other. In the case of Sp3, at
least three polypeptides are known to be produced from the
same mRNA by alternate use of translational initiation
codons (26,38). In the present study, at least four polypeptides
were seen that formed two closely migrating doublets
with approximate molecular mass of 115 and 70 kDa
(Figure 6). The expression of either the Sp1 or the Sp3 poly-
peptides was not affected by incubation of the cells with
TGF-b (Figure 6).
DISCUSSION
TGF-b has recently been shown to play a key anti-atherogenic
role (11–23). Consistent with such a role, we show here that
the cytokine inhibits the expression in macrophages of LPL
(Figures 1 and 2), which has been implicated in the uptake of
lipid/lipoproteins and the transformation of macrophages
into foam cells (1,2). This ﬁnding also correlates well with
previous studies showing that the cytokine inhibits foam cell
formation by suppressing the expression of scavenger receptor
A and CD36, which are involved in lipid/lipoprotein uptake,
and stimulating the expression of ABCA1 and ABCG1,
which have been implicated in enhancing cholesterol efﬂux
(11–14). We show that the TGF-b-mediated inhibition of
macrophage LPL gene expression is mediated at the transcrip-
tional level and that the  31/+187 region contains the TGF-
bREs (Figure 3). We demonstrate that three binding sites for
Sp1 and Sp3 in this region are essential for the response
(Figures 4 and 5).
Sp1 and Sp3 belong tothe zinc ﬁnger class oftranscriptional
regulators, which bind to an identical recognition sequence
and tend to be co-expressed in several tissues and cell types,
including macrophages (26,39). While these proteins were
originally implicated in the constitutive expression of several
genes, they have subsequently been shown to be involved in
inducible gene expression that includes responses triggered by
TGF-b (39). Although the Smads are largely responsible for
the transcriptional activation of these genes, other factors have
also been found to play an important role, including Sp1/Sp3
(40–45). For example, Sp1/Sp3 have been implicated in the
TGF-b-induced expression of tenascin-C, adenine nucleotide
translocator 1, endoglin, a2(I) collagen, p15 (Ink4B) cyclin-
dependent kinase inhibitor, urokinase type plasminogen activ-
ator receptor and several others (40–45). In many cases Sp1
acts in conjunction with Smads (40,41,43,44). TGF-b is also
known to inhibit the expression of a number of genes (24,25).
However, in contrast to gene activation, the mechanisms
responsible for transcriptional inhibition by the cytokine
have been identiﬁed for only a few genes, and include the
Smad3-mediated stimulation of expression of repressors
that then interact with their recognition sequence in the pro-
moter region of target genes (e.g. ATF-3 for Id1, SIP1 for
Time (h)      0             6             12           18        24 
Sp1
Sp3
Figure 6. The effect of TGF-b on steady-state levels of Sp1 and Sp3 polypep-
tides. Western-blot analysis was carried out using whole cell extracts from
J774.2 macrophages exposed to TGF-b1 (30 ng/ml) for the times indicated.
TheblottedmembraneswereprobedwithantiserumagainstSp1orSp3,andthe
antigen–antibodycomplexesweredetectedasdescribedinMaterialsandMeth-
ods. The position of the Sp1 and Sp3 polypeptides are shown on the right-hand
side of the figure. The data shown are representative of three independent
experiments.
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synthase 2) (46–48). In the case of Sp1 and Sp3, although Sp1
acts mainly as an activator of gene transcription, Sp3 contains
a transcriptionally repressive domain and can act as an activ-
ator or a repressor, depending on the promoter and cell type
(39). Interestingly, the TGF-b-mediated downregulation of
human type II collagen expression in articular chondrocytes
occurs through changes in the Sp3/Sp1 ratio (49). It was found
that TGF-b increased the expression of Sp3 in articular chon-
drocytes without signiﬁcant changes to its binding level, but
repressed both the synthesis and binding activity of Sp1 (49).
A similar transcriptional regulation of TGF-b1 receptor is also
dependent uponthe Sp1/Sp3 ratio (50).The mechanism for the
regulation of the LPL gene, however, appears to be different
from these cases given that there are no changes in both the
expression of Sp1 and Sp3 in macrophages and their binding
to recognition sequences in the regulatory region (Figures 4
and 6). Finally, TGF-b is also known to inhibit differentiation
of myoblasts, osteoblasts and adipocytes through Smad3-
mediated functional repression of key transcription factors
involved in the differentiation programme (e.g. Runx2/
CBFA1, MyoD and C/EBPs for the differentiation of osteo-
blasts, myoblasts and adipocytes, respectively) (51–53). A
TGF-b-mediated modulation of the trans-activation potential
of Sp1 and Sp3 remains the most likely mechanism for the
regulation of LPL gene expression. This could involve post-
translational modiﬁcation of Sp1/Sp3, limited availability of
co-activators shared with factors whose expression is induced
by TGF-b, or a cytokine-mediated interaction(s) with speciﬁc
co-repressors.
A role for Sp1 and Sp3 in the constitutive expression of LPL
has been reported previously (54). This site (position  91 to
 83) coincides with a naturally occurring  73T/G substitu-
tion that is associated with decreased promoter activity (54).
Sp1 and Sp3 in nuclear extracts from THP-1 macrophages
were shown to speciﬁcally interact with this site (54). This
site, however, is clearly not necessary for the TGF-b response
as its deletion does not affect the cytokine-mediated inhibition
of LPL promoter activity (Figure 3).
Although binding sites for Sp1 members are present in the
regulatory regions of a large number of genes, they are subject
to differential regulation by TGF-b, with the cytokine either
inducing or inhibiting the expression or having no effect. The
precise reason(s) for such differential regulation of gene
promoters by the Sp1 family remain currently unclear. The
consensus sequence for binding by Sp1 is GGGGCGGGG
(GC-rich boxes) or GGTGTGGGG (GT/CACC boxes) (39).
However, Sp1 members have also been found to interact
with sequences that diverge from this consensus (39). It is
interesting to note that the Sp1 recognition sequences identi-
ﬁed in the LPL gene (Figure 4B) diverge from this consensus.
It is, therefore, possible that such variations in the Sp1/
Sp3-binding sites between different regulatory regions
could be responsible for the differential actions of TGF-b.
An alternative explanation for the differential action could
be the involvement of sites for two or more transcription
factors in the response. Indeed, as detailed above, the Sp1
sites have been shown to act in conjunction with sites for
other transcription factors (40,41,43,44).
TGF-b and IFN-g often have opposite effects in a range of
cellular functions (55). It has been shown that IFN-g induces
the expression of Smad7, an antagonistic Smad, which
prevents the interaction of Smad3 with the TGF-b receptor
(55). In contrast to such ﬁndings, both IFN-g and TGF-b
inhibit LPL gene transcription and the responses are mediated
through Sp1 and Sp3 [(26–28); this study]. However, the
mechanisms by which IFN-g and TGF-b mediate the response
difference. Thus, in contrast to TGF-b, IFN-g reduces the
binding of Sp1 and Sp3 by decreasing the DNA-binding activ-
ity of Sp1 and the steady-state polypeptide levels of Sp3 (26).
In conclusion, we have identiﬁed a novel pathway by which
TGF-b inhibits LPL gene transcription that involves modula-
tion of the action of Sp1 and Sp3. Future studies should seek to
identify the signal transduction pathways involved in the
response and the molecular mechanisms by which TGF-b
modulates Sp1 and Sp3.
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